Quanterix Corporation

QTRX

US74766Q1013

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
16.93 ^USD	+0.89%		-5.31%	-38.08%

05-08	Transcript : Quanterix Corporation, Q1 2024 Earnings Call, May 08, 2024
05-07	Earnings Flash (QTRX) QUANTERIX CORPORATION Posts Q1 Revenue $32.1M, vs. Street Est of $31.5M	MT

Quanterix Corporation Announces Resignation of John Fry as General Counsel and Secretary, Effective August 12, 2022

June 24, 2022 at 09:05 pm

Quanterix Corporation announced that on June 21, 2022, John Fry notified the Company of his resignation as General Counsel and Secretary, effective August 12, 2022.

Latest news about Quanterix Corporation

Transcript : Quanterix Corporation, Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (QTRX) QUANTERIX CORPORATION Posts Q1 Revenue $32.1M, vs. Street Est of $31.5M	05-07	MT
Quanterix Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Quanterix Corporation Provides Earnings Guidance for the Full-Year 2024	05-07	CI
Canaccord Genuity Adjusts Price Target on Quanterix to $25 From $32, Maintains Buy Rating	04-29	MT
Quanterix Corporation Announces Laurie Olson, Director Will Not Stand for Re-Election	04-12	CI
Transcript : Quanterix Corporation - Special Call	03-25
Scotiabank Raises Price Target on Quanterix to $32 From $30, Keeps Sector Outperform Rating	03-04	MT
Quanterix Corporation Receives Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer?s Disease	03-04	CI
Quanterix Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Transcript : Quanterix Corporation, Q4 2023 Earnings Call, Feb 29, 2024	02-29
Quanterix Corporation Provides Earnings Guidance for the Year 2024	02-29	CI
Quanterix Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q4 Revenue $31.5M, vs. Street Est of $29.8M	02-29	MT
Quanterix Corporation Reaffirms Earnings Guidance for the Year 2023	02-26	CI
Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer?S Disease	02-26	CI
Transcript : Quanterix Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	01-11
Transcript : Quanterix Corporation, Q3 2023 Earnings Call, Nov 07, 2023	11-07
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M	11-06	MT
Quanterix Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $31.3M, vs. Street Est of $27.6M	11-06	MT
Quanterix Corporation Revises Earnings Guidance for the 2023	11-06	CI
Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer's Disease	24/10/23	CI
Quanterix Signs License Deal for Johnson & Johnson's p-Tau 217 Antibodies, Assay Designs	24/10/23	MT
Blood tests needed for widespread Alzheimer's diagnosis on the way	11/10/23	RE

Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.

Sector

Advanced Medical Equipment & Technology

Calendar

03/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Quanterix Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.93 USD

Average target price

28.4 USD

Spread / Average Target

+67.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
QUANTERIX CORPORATION	-38.08%	648M
THERMO FISHER SCIENTIFIC	+11.31%	226B
DANAHER CORPORATION	+15.50%	198B
INTUITIVE SURGICAL, INC.	+18.83%	142B
BOSTON SCIENTIFIC CORPORATION	+30.38%	111B
SIEMENS HEALTHINEERS AG	+2.66%	65.26B
EDWARDS LIFESCIENCES CORPORATION	+18.31%	54.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.96%	50.94B
AGILENT TECHNOLOGIES, INC.	+9.95%	44.8B
GE HEALTHCARE TECHNOLOGIES INC.	+4.27%	36.8B

Other Advanced Medical Equipment & Technology